For the last three decades, extracorporeal lung assist (ECLA) has been employed as a life-saving therapy in few highly-specialised centres. A deeper understanding of acute respiratory distress syndrome (ARDS) pathophysiology, improved technology and the positive results of recent trials have led to a reassessment of ECLA in the clinical setting. The referral and transfer of sicker patients to specialised extracorporeal membrane oxygenation (ECMO) centres has been shown to improve clinical outcome. The CESAR (conventional ventilator support versus extracorporeal membrane oxygenation for severe adult respiratory failure) trial was the first positive randomised controlled trial to investigate ECMO use in adult patients with ARDS. In 2009, many healthcare systems worldwide successfully faced the influenza A (H1N1) pandemic, instituting networks of specialised intensive care units (ICUs), for transfer of the sickest patients and management with ECMO. There is also an increasing interest in new and less invasive extracorporeal techniques, primarily aimed at carbon dioxide removal, which may be more widely applied in combination with a strictly protective ventilatory strategy.

Extracorporeal lung support to remove carbon dioxide / Terragni, P; Birocco, A; Ranieri, V M. - In: EUROPEAN RESPIRATORY MONOGRAPH. - ISSN 1025-448X. - 55:(2012), pp. 142-152. [10.1183/1025448x.10002411]

Extracorporeal lung support to remove carbon dioxide

TERRAGNI, Pierpaolo;
2012

Abstract

For the last three decades, extracorporeal lung assist (ECLA) has been employed as a life-saving therapy in few highly-specialised centres. A deeper understanding of acute respiratory distress syndrome (ARDS) pathophysiology, improved technology and the positive results of recent trials have led to a reassessment of ECLA in the clinical setting. The referral and transfer of sicker patients to specialised extracorporeal membrane oxygenation (ECMO) centres has been shown to improve clinical outcome. The CESAR (conventional ventilator support versus extracorporeal membrane oxygenation for severe adult respiratory failure) trial was the first positive randomised controlled trial to investigate ECMO use in adult patients with ARDS. In 2009, many healthcare systems worldwide successfully faced the influenza A (H1N1) pandemic, instituting networks of specialised intensive care units (ICUs), for transfer of the sickest patients and management with ECMO. There is also an increasing interest in new and less invasive extracorporeal techniques, primarily aimed at carbon dioxide removal, which may be more widely applied in combination with a strictly protective ventilatory strategy.
Extracorporeal lung support to remove carbon dioxide / Terragni, P; Birocco, A; Ranieri, V M. - In: EUROPEAN RESPIRATORY MONOGRAPH. - ISSN 1025-448X. - 55:(2012), pp. 142-152. [10.1183/1025448x.10002411]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11388/84539
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact